Advancing Novel Therapeutics for Women’s Reproductive Health

ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.

Our Pipeline

Overview

ObsEva is advancing three product candidates through clinical development across a total of four indications.

Product candidate

Preclincal

Phase 1

Phase 2

Phase 3

Next milestones

Commercial rights

Yselty® (Linzagolix)

Oral GnRH receptor antagonist


NDA submission (Q3:21)
.

.
MAA for uterine fibroids expected recommendation (Q4:21)


EDELWEISS 3: Primary endpoint readout expected (Q4:21)

.

.

.

Exclusive worldwide (ex-Asia)

Ebopiprant

Oral PGF2α receptor antagonist

Initiation Phase 2b dose ranging study in EU and Asia (Q4:21)

Exclusive worldwide

Nolasiban

Oral oxytocin
receptor antagonist

In development, partnership with Yuyuan BioScience Technology (PRC)


Exclusive worldwide (ex China)
Partnership with Yuyuan BioScience Technology (PRC)





Clinical Studies

We are currently conducting three international clinical research studies.

Read more

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue